Skip to content

Effect of Jujube Oxymel in Chronic Urticaria

The Efficacy and Safety of Jujube Oxymel in Chronic Spontaneous Urticaria, A Double-Blind, Randomized, Clinical Trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200201046328N1
Enrollment
106
Registered
2020-07-01
Start date
2020-06-21
Completion date
Unknown
Last updated
2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Urticaria. Other urticaria: chronic spontaneous urticaria

Interventions

Intervention 1: Intervention group: receiving orally Jujube Oxymel syrup with the licence of Medical Equipment Department by Sobh Omid Mah Noor Company, three times a day, each time 30 cc for one mont

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with chronic urticaria with doctor confirmation 12 to 65 years old Male and female Have tendency for entering into study Not using any anti urticaria medications during the past week

Exclusion criteria

Exclusion criteria: Pregnancy & breast-feeding Having severe angioedema Having uncontrolled cardiovascular, respiratory, hematologic, urology, immune system, infectious and diabetes Having sensitivity to antihistamine drugs Having sensitivity to Jujube plant

Design outcomes

Primary

MeasureTime frame
Quantity of hives. Timepoint: First of research, 7,14,21,28,56 days after intervention. Method of measurement: Urticaria Activity Score (UAS) questionnaire.;Level of itch. Timepoint: First of research, 7,14,21,28,56 days after intervention. Method of measurement: Urticaria Activity Score (UAS) questionnaire.;Quality of life. Timepoint: First of research, fourth and eighth weeks of study. Method of measurement: Quality of Life Questionnaire of chronic urticaria CU-Q2oL.

Secondary

MeasureTime frame
Sides effects. Timepoint: Fourth and eighth weeks of the study. Method of measurement: Common Terminology Criteria for Adverse Events v5.0 2017.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Taghavi Shirazi

Iran University of Medical Sciences

Taghavi.shirazi.m@iums.ac.ir+98 21 5515 2191

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026